177Lu-SN201药物候选者继续第一阶段/IIa试验Tumourad-01,在DMC发现对前三名病人安全后接受高级癌症治疗。 177Lu-SN201 drug candidate continues Phase I/IIa trial Tumorad-01 for advanced cancer treatment after DMC finds it safe for first three patients.

瑞典生物制药公司Spago Nano medical的第一阶段/IIa Tumourad-01试验,评价其药物候选者177Lu-SN201的高级癌症治疗,在独立的数据监测委员会(DMC)发现前3名病人的药物安全后,该试验继续进行。 Swedish biopharm firm Spago Nanomedical's Phase I/IIa trial Tumorad-01, evaluating its drug candidate 177Lu-SN201 for advanced cancer treatment, continues after an independent Data Monitoring Committee (DMC) found the drug safe for first three patients. 目前正在为各种肿瘤类型招募病人,目的是确定治疗剂量,以便在研究的第二阶段a部分进一步测试。 Patient recruitment for various tumor types is ongoing, aiming to identify a therapeutic dose for further testing in the Phase IIa part of the study. 成功的结果可能导致多种癌症类型的潜在用途。 Successful results could lead to potential use in multiple cancer types.